Hormonal

Peripheral administration of the recombinant GLP-1-albumin fusion protein Albugon activates central nervous system (CNS) satiety and gastrointestinal pathways via vagal afferents, despite its large size preventing direct blood-brain barrier crossing.

This research suggests that large, long-acting GLP-1 therapies (like Albugon) can reduce appetite and improve blood sugar even though they are too big to enter the brain directly. Instead, they stimulate nerves in the gut (vagal afferents) that send signals to the brain's satiety centers. This validates the design of long-acting GLP-1 drugs that rely on peripheral signaling to achieve central effects like reduced hunger.